Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, TX, USA.
Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Future Oncol. 2021 Dec;17(35):4971-4982. doi: 10.2217/fon-2021-0901. Epub 2021 Oct 5.
Locally advanced or metastatic cutaneous squamous cell carcinoma no longer amenable to surgical resection or primary radiation therapy requires an alternative approach to treatment. Until 2018, management consisted of limited systemic chemotherapies, which carried marginal clinical benefit. The introduction of immunotherapy with anti-PD-1 antibodies resulted in alternative treatment options for advanced cutaneous squamous cell carcinoma with substantial antitumor activity, durable response and acceptable safety profile. The field of immunotherapeutics continues to expand with adjuvant, neoadjuvant and intralesional studies currently in progress. Herein, the authors discuss their approach for the treatment of advanced cutaneous squamous cell carcinoma from the perspective of a Mohs surgeon and a dermatologic oncologist.
局部晚期或转移性皮肤鳞状细胞癌，经手术切除或原发放疗后无法治愈，需要采取替代治疗方法。直到 2018 年，治疗方法包括有限的全身化疗，但临床获益有限。抗 PD-1 抗体免疫治疗的引入为晚期皮肤鳞状细胞癌提供了替代治疗方案，具有显著的抗肿瘤活性、持久的缓解和可接受的安全性。免疫治疗领域仍在不断发展，目前正在进行辅助、新辅助和瘤内研究。本文作者从 Mohs 外科医生和皮肤肿瘤学家的角度讨论了治疗晚期皮肤鳞状细胞癌的方法。
